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Abstract  
Purpose.  To conduct a pooled analysis assessing the association of blood transfusion with risk 
of non-Hodgkin lymphoma (NHL). 
Methods.  We used harmonized data from 13 case-control studies (10,805 cases, 14,026 
controls) in the InterLymph Consortium.  Odds ratios(OR) and 95% confidence intervals(CI) 
were calculated using unconditional logistic regression, adjusted for study design variables. 
Results.  Among non-Hispanic whites (NHW), history of any transfusion was inversely 
associated with NHL risk for men (OR=0.74; 95%CI 0.65-0.83) but not women (OR=0.92; 
95%CI 0.83-1.03), Pheterogeneity=0.014.  Transfusion history was not associated with risk in other 
racial/ethnic groups.  There was no trend with the number of transfusions, time since first 
transfusion, age at first transfusion, or decade of first transfusion, and further adjustment for 
socioeconomic status, body mass index, smoking, alcohol use and HCV seropositivity did not 
alter the results.  Associations for NHW men were stronger in hospital-based (OR=0.56; 95%CI 
0.45-0.70) but still apparent in population-based (OR=0.84; 95%CI 0.72-0.98) studies. 
Conclusions.  In the setting of a literature reporting mainly null and some positive associations, 
and the lack of a clear methodologic explanation for our inverse association restricted to NHW 
men, the current body of evidence suggests that there is no association of blood transfusion 
with risk of NHL. 
     
Keywords:  transfusion; lymphoma; etiology; epidemiology; pooled analysis   
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Abbreviations 
BMI  Body mass Index 
DLBCL Diffuse large B-cell lymphoma 
FL  Follicular lymphoma 
HIV  Human immunodeficiency virus 
NHL  Non-Hodgkin lymphoma 
NHW  Non-Hispanic whites 
SES  Socioeconomic status 
TCL  T-cell lymphoma 
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Introduction 
The use of allogeneic blood transfusions increased dramatically after World War II until the 
1970s, when concerns about transmitting infectious agents, including Hepatitis B and C and 
human immunodeficiency virus (HIV) led to a decline in use [1].  Transmission of infectious 
agents linked to NHL, along with the immunologic impacts of blood transfusions [2], suggest this 
exposure could be a risk factor for NHL.  In a 2010 meta-analysis of 9 case-control and 5 cohort 
studies [3], blood transfusions were associated with an increased risk of NHL (RR=1.20; 95% CI 
1.07-1.35).  Results were similar for transfusions given before or after 1992 (a surrogate for 
increased viral screening and leukodepletion) and by gender.  Heterogeneity was observed by 
study design, with an association observed only in cohort (RR=1.34; 95% CI 1.15-1.55) but not 
case-control (OR=1.05; 95% CI 0.89-1.25) studies.  In a subset of the studies with NHL subtype 
data, transfusion history was associated with CLL/SLL but not DLBCL or FL.  However, the 
meta-analysis was limited by use of older studies, exposure categories only available from 
publications, and inability to systematically assess for potential confounding factors or subgroup 
specific associations.  Most importantly there was a lack of systematic assessment of NHL 
subtypes and limited power to assess NHL subtype-specific associations. 
History of blood transfusion was recently evaluated as part of the InterLymph NHL Subtypes 
Project [4], using individual level harmonized data from 13 case-control studies, of which four 
US studies [5-8]  were included in the prior meta-analysis [3].  In the Subtypes Project, history of 
blood transfusion before 1990 was inversely associated with risk of NHL overall (OR=0.76; 95% 
CI 0.67-0.87) but with evidence for heterogeneity by NHL subtype (P=0.013) [9].  In subtype-
specific adjusted models, the NHL subtypes showing statistically significant inverse associations 
were DLBCL (OR=0.69; 95% CI 0.57-0.83) [10], FL (OR=0.78; 95% CI 0.68-0.89) [11], and 
CLL/SLL (OR=0.69; 95% CI 0.66-0.94) [12].  To better understand  these unexpected results, 
we conducted a more detailed analysis of transfusion history with risk of NHL i
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Subtypes Project, focusing on population characteristics (race/ethnicity, gender, geographic 
region, socioeconomic status (SES), prevalence of exposure), study characteristics (population-
based vs other; control response rates), and potential confounding factors related to transfusion 
history. 
 
Materials and Methods 
Study population 
Participating studies in this pooling project were all members of the InterLymph Consortium 
(http://www.epi.grants.cancer.gov/InterLymph) that met the following criteria:  case-control 
design with incident cases of NHL diagnosed age 16 years or older; collection of data on 
transfusion history; and availability of individual level data by December 31, 2011.  A total of 13 
case-control studies (Table 1) were included [4].  The sites comprising EpiLymph and NCI-
SEER were analyzed individually to allow for assessment of center-specific effects and 
heterogeneity.   
Case patients were identified through rapid case ascertainment systems and diagnoses 
were confirmed using review of pathology reports or diagnostic slides by study pathologists.  All 
but two studies (NCI-SEER and Italy multicenter studies) had centralized pathology review.  As 
previously reported [4], we grouped cases into NHL subtypes (including cases from the Working 
Formulation) according to the WHO Classification [13, 14] using guidelines from the InterLymph 
Pathology Working Group [15, 16].   
Controls were frequency matched on age, sex and other design characteristics, and were 
randomly selected from population registers, random digit dialing, neighborhood matching, or 
from hospital or clinic patients.  With the exception of the Iowa/Minnesota study, which used 
proxy respondents for deceased cases, all other studies were restricted to living cases.  The 
Yale study enrolled only women and the Iowa/Minnesota study enrolled only men.  Most studies 
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excluded individuals with a history of solid organ transplantation or HIV/AIDS; if not, they were 
excluded from this pooled analysis.  All contributing studies were approved by local ethics 
committees, and all participants provided informed consent. 
  
Risk factor assessment and harmonization 
Each study collected risk factor data using a standardized questionnaire that was either self-
administered or interviewer-administered (in-person or by telephone).  Each study contributed 
de-identified, individual-level data for study design variables, NHL subtype, transfusion history, 
and potential confounding factors including medical history, family history of hematologic 
malignancy, and lifestyle.  Data harmonization was conducted at the InterLymph Data 
Coordinating Center, as previously described [4].   
History of blood transfusion included history of any blood transfusion occurring 1 or more 
years prior to diagnosis/interview, number of transfusion events, and age and year of first 
transfusion.  Too few studies had indication for blood transfusion or type and quantity of 
blood/blood product transfused to use in this analysis.   
Potential confounding factors available from four or more studies included education/SES, 
categorized as low, medium and high; family history of any hematologic malignancy in a first 
degree relative; obesity based on body mass index, and GHILQHGDVYHUVXV!NJP2; 
cigarette smoking history, defined as never, former or current; alcohol use, defined as never, 
former or current; history of rheumatoid arthritis; history of hay fever; lifetime recreational sun 
exposure, defined as quartiles of recreational sun exposure in hours/week; and serum 
antibodies to hepatitis C virus based on third generation ELISA [17].  Full details on these 
variables and their harmonization are available elsewhere [4]. 
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Statistical analysis 
We used descriptive statistics to estimate the prevalence of transfusion history among controls 
by age, sex, and race/ethnicity; 95% confidence intervals (CI) were calculated using a normal 
approximation to the binomial distribution.  To compare across studies, we calculated 
prevalence of transfusion history adjusted for age and sex. 
We used odds ratios (ORs) and 95% CI from unconditional logistic regression models to 
estimate the association of transfusion history with NHL risk.  Basic models were adjusted for 
age, sex and study center.  The statistical significance of each association was evaluated by a 
likelihood ratio test, comparing models with and without the exposure of interest, with P-values 
<0.05 identifying potentially significant factors.  We first assessed heterogeneity by 
race/ethnicity and then by sex.  We tested for heterogeneity by calculating the Wald statistic for 
the interaction term between each exposure and stratification variable.  We also used meta-
analysis and forest plots to further evaluate heterogeneity by study characteristics.  To evaluate 
confounding, we compared basic models with models including additional factors previously 
suggested as NHL risk factors that were available in at least four of the studies.  Finally, for 
analyses of NHL subtypes, we used polytomous logistic regression.   All analyses were 
conducted using SAS software, version 9.2 (SAS Institute, Inc, Cary NC). 
 
Results  
The pooled study population consisted of 10,805 cases and 14,026 controls.  Cases compared 
to controls were well-balanced on sex, age at diagnosis/recruitment, race/ethnicity, and 
education/SES (Supplementary Table 1).  The median age of cases was 60 years (range 18-97) 
and of controls was 59 years (range 16-97).  The most common NHL subtype was diffuse large 
B-cell lymphoma (DLBCL) (30.2%) followed by follicular lymphoma (FL, 23.5%), while T-cell 
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lymphomas were uncommon (TCL, 5.5%); 0.8% of the cases did not have a subtype 
classification.   
Among controls, the prevalence of ever having had a blood transfusion increased with age 
and was higher for women (18%) than men (13%) (Supplementary Figure 1).  The age and sex 
adjusted prevalence of transfusion among controls varied from 11.3% to 21.7% across studies 
(Figure 1).  There was no evident correlation between prevalence of transfusion and study 
region (Figure 1) or hospital versus population-based study design (Supplementary Figure 2).  
The age and sex adjusted prevalence of transfusion among controls was quite similar across 
race/ethnicity groups by sex, with perhaps a lower prevalence among Asian women 
(Supplementary Figure 3).   
Transfusion history was inversely associated with risk of NHL for men (OR=0.75; 95% CI 
0.67-0.84) but not women (OR=0.94; 95% CI 0.85-1.04), and this difference was statistically 
significant (P=0.014).  These associations were largely driven by non-Hispanic whites 
(Supplementary Table 2 and Supplementary Figure 4), as the other racial/ethnic groups showed 
highly variable and imprecise associations, mainly driven by small sample sizes.  Based on 
these results, the remaining analyses are restricted to this group and are stratified by sex. 
For non-Hispanic white men, the inverse association of transfusion with NHL risk was 
slightly stronger for one (OR=0.70; 95% CI 0.60-0.81) than for two or more (OR=0.81; 95% CI 
0.65-1.00) transfusions compared to no transfusions (Table 2).  No dose-response effects were 
observed for time since first transfusion, age at first transfusion, or decade of first transfusion.  
For non-Hispanic white women, having had any transfusion was weakly associated with NHL 
risk (OR=0.92; 95% CI 0.83-1.03), although an inverse association was observed for two or 
more transfusions (OR=0.76; 95% CI 0.36-0.92) compared to no transfusions.  No consistent 
associations were observed with time since first transfusion, age at first transfusion or decade of 
first transfusion   
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The prevalence of transfusion history among controls for selected NHL risk factors among 
controls is shown in Table 3.  Overall, only SES, never smoking (for men), and recreational sun 
exposure showed greater than 5% difference in prevalence of transfusion history between 
cases and controls.  Adjustment for each of these factors in the basic model did not alter the 
associations reported in Table 3 (data not shown).  We had HCV serology on a subset of 1310 
cases and 1889 controls, and a positive serology was more common in controls with a 
transfusion history than those with no history for both men (5.0% vs. 3.2%) and women (6.0% 
vs. 2.7%).  Adjustment for HCV serology attenuated the weak inverse transfusion association 
towards the null for women (OR=1.02; 95% CI 0.67-1.55) but did not alter the association for 
men (OR=0.69; 95% CI 0.48-0.99). 
Results for the association of transfusion with NHL risk varied by study design.  For men, the 
pooled risk estimates were stronger for hospital-based studies (OR=0.56; 95% CI 0.45-0.70) 
relative to population-based studies (OR=0.84; 95% CI 0.72-0.98).  In contrast, for women, the 
transfusion and NHL association was nearly identical for hospital-based (OR=0.91; 95% CI 
0.75-1.10) and population-based (OR=0.93; 95% CI 0.82-1.06) studies.   
We next explored whether results differed by study region (Figure 2).  For men, the inverse 
association was strongest for studies from southern Europe (OR=0.53; 95% CI 0.36-0.79), 
intermediate for Northern Europe (OR=0.62; 95% CI 0.49-0.79), and weakest but still evident for 
North America (OR=0.83; 95% CI 0.71-0.98).  For women, there was little heterogeneity by 
study region.   
NHL subtype-specific associations with transfusion history by sex are shown in a forest plot 
(Figure 3).  For men, there were statistically significant inverse associations with follicular 
lymphoma, DLBCL, and CLL/SLL, and ORs were less than 1 for all of the other subtypes except 
for Mycosis Fungoides/Sezary Syndrome (OR=1.07).  For women, a statistically significant 
inverse association with follicular lymphoma, and suggestive inverse associations with CLL/SLL 
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and PTCL were observed.  In contrast, several subtypes showed suggestive elevations in risk 
with transfusion history, but none of the results were statistically significant.  
 
Discussion 
In this pooled analysis of 13 studies, which provided over 10,000 cases and 14,000 controls, we 
found an inverse association of self-reported blood transfusion history with risk of NHL that was 
confined to non-Hispanic white men, and was specific to follicular lymphoma, DLBCL and 
CLL/SLL.  These results were not confounded by lifestyle factors or HCV seropositivity, nor 
were they explained by era of first transfusion, geographic region of the study, or hospital versus 
population-based study design. 
Strengths of this pooled analysis included the large sample size with studies from multiple 
geographic regions, systematic evaluation of NHL subtype, harmonized data on transfusion and 
potential confounders, careful assessment of confounding, and some, albeit limited, data by 
race/ethnicity.  The major limitations are the potential bias arising from the use of the case-
control study design, lack of validation of self-reported transfusion history, limited data on 
characteristics of the transfusion and no data about the type of blood or indication for 
transfusion.       
The inverse association among men was unexpected, and it is uncertain if the association is 
due to bias.  In the Castillo et al. meta-analysis, risk estimates were similar for men (RR=1.19; 
95% CI 1.03-1.38) and women (RR=1.26; 95% CI 1.09-1.45).  Era of transfusion overlaps the 
cohort studies that have reported a positive association.  While the case-control studies in the 
Castillo et al. meta-analysis [3] showed no evidence of an association with transfusion history, 
this included only four [5-8] of the 13 studies reported here.  We were unable to assess 
confounding by indication, although it is unclear what type of medical indication would generate 
an inverse association.  It is not clear that confounding by other NHL risk factors (or unknown 
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confounders) is an explanation, as we found little evidence for this, and negative confounding 
would be needed to generate an inverse association.  Recall bias is always a concern in case-
control studies, but to generate an inverse association, controls would need to systematically 
over-report (or cases under-report) transfusion history, a situation for which we have no 
supportive evidence.  Finally, selection bias, through differential participation or source of cases 
and controls might be an explanation, and we did see a stronger inverse association among 
hospital versus population-based studies, with the hospital-based control group perhaps 
enriched for prior exposure to blood transfusions.  Yet none of these are particularly compelling 
explanations and our findings could be a false positive result.   
As discussed above, the five cohort studies in the Castillo et al. meta-analysis [3] were 
associated with an increased risk of NHL (RR=1.34; 95% CI 1.15-1.55).  Since that publication, 
a large population-based case-control study nested in the SEER-Medicare cohort (all subjects 
age 65 years and older) reported that blood transfusion (obtained from linked records) was 
positively associated with risk of NHL (OR=1.17; 95% CI 1.12-1.23) and was specifically 
elevated for DLBCL, MZL, CLL, LPL and TCL, but not FL [18].  However, except for LPL and 
MZL the strongest ORs were observed for the shortest latency (<2 years), suggesting the effect 
was due to reverse causality, consistent with results of other studies [8, 19, 20].  The SEER-
Medicare study also reported stronger ORs for the association of transfusion with NHL risk for 
transfusions given for GI bleeding and unspecified anemia, relative to surgical procedures, 
which has been reported in other studies [5, 6].  This raises concerns of either reverse causality 
(lymphoma causing anemia) or confounding by indication of medical conditions associated with 
both risk of transfusion and NHL.  In the Million Women Study [21], history of blood transfusion 
after 2000 (modern era of intense viral screening) was ascertained from electronic hospital 
records.  In that study, there was also an elevated risk of NHL <5 years after transfusion 
(RR=4.69; 95% CI 3.79-5.82).  Interestingly, risk was also elevated more than 5 years 
subsequent to transfusion (RR=2.63; 95% CI 1.45-4.78) and only slightly attenuated following 
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adjustment for smoking, alcohol use, and body mass index.  Finally, in a Scandinavian study 
that linked population, blood bank and health care registers, there was no evidence that blood 
transfusions from donors who later developed cancer were associated with risk of lymphoma 
[22] oUWKDWWUDQVIXVLRQUHFLSLHQWV¶ULVNRI&//ZDVDIIHFWHGE\SRVW-donation CLL in the donor 
(i.e., that the donor presumably had the precursor monoclonal B-cell lymphocytosis at time of 
donation) [23]. 
In summary, in a large, pooled analysis of 13 case-control studies we observed an 
unexpected inverse association of transfusion history with NHL risk, but restricted to the 
subgroup of non-Hispanic white men and lacking any dose-response.  In the setting of a 
literature reporting mainly null or positive associations, and the lack of a clear methodologic 
explanation for our results, the current body of evidence provides little support for a causal 
association of transfusion history with risk of NHL.   
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Table 1.  Characteristics of case-control studies included in the pooled analysis 
      
Cases 
 
Controls 
Study Name 
(reference) Location Years 
Age 
Range Design 
Pathology 
Classification N 
Partici-
pation 
Rate   N 
Partici
-pation 
Rate 
British Columbia Vancouver, Victoria, British Columbia 
(Canada) 
2000-2004 20-82 Population-based WHO/ICD-O-3 833 79%  848 46% 
Engela Bordeaux, Brest, Caen,  Lille, Nantes, 
Toulouse (France) 
2000-2004 18-76 Hospital-based WHO/ICD-O-3 567 93%  722 97% 
EpiLymph-Czech 
Republic 
Single center in Czech Republic 2001-2003 18-80 Hospital-based WHO 181 90%  304 60% 
EpiLymph-France Amiens, Dijon, Montpellier 2000-2003 18-80 Hospital-based WHO 215 91%  276 74% 
EpiLymph-Germany Ludwigshafen/Upper Palatinate, 
Heidelberg/Rhine-Neckar County, 
Wurzburg/Lower Franconia, Hamburg, 
Bielefeld, Munich 
1999-2002 18-80 Population-based WHO 518 88%  710 44% 
EpiLymph-Ireland Six hospitals on the East Coast of the 
Republic of Ireland 
2001-2003 18-80 Hospital-based WHO 136 90%  208 75% 
EpiLymph-Italy Sardinia 1998-2004 18-80 Population-based WHO 183 93%  336 66% 
EpiLymph-Spain Barcelona, Tortosa, Reus and Madrid 1998-2004 18-80 Hospital-based WHO 439 82%  631 96% 
Iowa-Minnesota Iowa and Minnesota (USA) 1981-1983 30-97 Population-based Working Formulation 866 87%  1245 81% 
Italy Aviano and Naples, Italy 1999-2002 18-84 Hospital-based WHO 225 97%  504 91% 
Los Angeles Los Angeles, California 1989-1992 17-79 Population-based Working Formulation 378 45%  378 69% 
Mayo Clinic Minnesota, Iowa, Wisconsin 2002-2008 18+ Clinic-based WHO 1128 69%  1319 69% 
NCI-SEER Detroit, Michigan; Iowa; Los Angeles, 
California; Seattle, Washington (USA) 
1998-2001 20-70 Population-based WHO/ICD-O-2 1321 76%  1057 52% 
Nebraska Nebraska (USA) 1999-2002 20-75 Population-based WHO 386 74%  533 77% 
New South Wales New South Wales, Australian Capital 
Territory (Australia) 
2000-2001 20-74 Population-based WHO/ICD-O-3 694 85%  694 61% 
UCSF San Francisco, California (USA) 1988-1995 21-74 Population-based Working Formulation 1302 72%  2402 78% 
United Kingdom Yorkshire, Lancashire, South Lakeland and 
parts of Southwest England 
1998-2003 16-69 Population-based ICD-O-3 833 70%  1142 69% 
Yale Connecticut (USA) 1995-2001 21-84 Population-based REAL 600 72%   717 47%-
69% 
Total 
     
10805 
  
14026 
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Table 2.  Association of blood transfusion with risk of NHL for whites by sex 
 Men  Women 
 Controls  Cases     Controls  Cases    
Transfusion exposure N %  N % OR* 95% CI   N %  N % OR* 95% CI 
History of blood transfusion                  
   No 5473 86.9%  4111 89.4% 1.00 reference  4205 80.8%  3307 81.4% 1.00 reference 
   Yes 824 13.1%  488 10.6% 0.74 0.65 0.83  997 19.2%  754 18.6% 0.92 0.83 1.03 
   Missing 1123   925      150   122     
                  Number of blood transfusions                  
   One 540 8.6%  303 6.6% 0.70 0.60 0.81  675 13.0%  544 13.4% 1.01 0.89 1.14 
   Two or more 241 3.9%  157 3.4% 0.81 0.65 1.00  301 5.8%  196 4.8% 0.76 0.63 0.92 
   Missing 1166   953      171   136     
                  Years from 1st transfusion to date of diagnosis/interview 
   1-4 years 130 2.1%  76 1.7% 0.76 0.57 1.02  96 1.8%  65 1.6% 0.86 0.62 1.18 
   5-9 years 131 2.1%  81 1.8% 0.75 0.56 1.00  100 1.9%  70 1.7% 0.88 0.65 1.21 
   10-20 years 217 3.4%  142 3.1% 0.82 0.66 1.02  182 3.5%  137 3.4% 0.95 0.76 1.20 
   21-39 years 237 3.8%  119 2.6% 0.64 0.51 0.81  410 7.9%  328 8.1% 0.97 0.83 1.14 
   40+ years 109 1.7%  70 1.5% 0.73 0.54 1.00  209 4.0%  154 3.8% 0.86 0.69 1.07 
   Missing 1123   925      150   122     
                  Age at 1st transfusion (years)                  
    141 2.2%  97 2.1% 0.91 0.70 1.19  135 2.6%  103 2.5% 0.96 0.74 1.25 
   21-30 140 2.2%  65 1.4% 0.61 0.45 0.82  273 5.2%  249 6.1% 1.13 0.95 1.36 
   31-40 109 1.7%  62 1.3% 0.71 0.51 0.97  222 4.3%  143 3.5% 0.78 0.63 0.97 
   41-50 127 2.0%  66 1.4% 0.68 0.50 0.92  150 2.9%  117 2.9% 0.94 0.73 1.20 
   51-60 134 2.1%  91 2.0% 0.79 0.60 1.05  99 1.9%  58 1.4% 0.70 0.50 0.97 
   >60 173 2.7%  107 2.3% 0.72 0.56 0.93  118 2.3%  84 2.1% 0.84 0.63 1.13 
   Missing 1123   925      150   122     
                  Era of first transfusion                  
   <1970 210 3.4%  113 2.5% 0.77 0.61 0.98  358 7.1%  267 6.8% 0.94 0.79 1.11 
   1970s 141 2.3%  56 1.2% 0.58 0.42 0.79  167 3.3%  152 3.9% 1.18 0.94 1.48 
   1980s 186 3.0%  114 2.5% 0.85 0.67 1.09  168 3.3%  109 2.8% 0.86 0.67 1.10 
   1990+ 190 3.1%  107 2.4% 0.66 0.52 0.84  155 3.1%  106 2.7% 0.92 0.71 1.19 
   Missing 1220     1023           299     242         
*OR (odds ratio) and 95% CI (confidence intervals), adjusted for age at diagnosis/interview and study center. 
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Table 3.  Prevalence of selected risk factors by sex and blood transfusion status among controls 
 
Men 
 
Women 
 
Never Transfused 
 
Ever Transfused 
 
Never Transfused 
 
Ever Transfused 
  N %   N %   N %   N % 
Socioeconomic status  
           
     low  3342 35.0% 
 
524 40.1% 
 
2977 39.7% 
 
799 45.7% 
     medium  2945 30.9% 
 
404 30.9% 
 
2410 32.2% 
 
588 33.7% 
     high  3257 34.1% 
 
379 29.0% 
 
2100 28.0% 
 
359 20.5% 
Family history of hematologic malignancy 
         
     No 8162 93.9% 
 
1129 94.2% 
 
6214 92.5% 
 
1442 91.4% 
     Yes 532 6.1% 
 
70 5.8% 
 
504 7.5% 
 
136 8.6% 
Body mass index (BMI) 
           
      kg/m2 6674 83.2% 
 
858 80.8% 
 
5530 83.4% 
 
1244 80.2% 
     >30 kg/m2 1348 16.8% 
 
204 19.2% 
 
1100 16.6% 
 
307 19.8% 
Smoking 
           
     Never 2905 35.2% 
 
316 28.6% 
 
3625 55.2% 
 
834 54.5% 
     Former 3407 41.2% 
 
561 50.9% 
 
1761 26.8% 
 
451 29.5% 
     Current 1948 23.6% 
 
226 20.5% 
 
1185 18.0% 
 
246 16.1% 
Alcohol 
           
     Never 802 16.5% 
 
114 17.3% 
 
1659 40.2% 
 
451 43.0% 
     Former 460 9.4% 
 
88 13.4% 
 
393 9.5% 
 
106 10.1% 
     Current 3606 74.1% 
 
456 69.3% 
 
2074 50.3% 
 
493 47.0% 
Recreational sun exposure 
          
     Quartile 1-2 2104 44.5% 
 
238 38.6% 
 
2865 64.2% 
 
688 68.9% 
     Quartile 3-4 2626 55.5% 
 
378 61.4% 
 
1600 35.8% 
 
311 31.1% 
Rheumatoid arthritis 
           
     No 8891 97.0% 
 
1150 93.0% 
 
6774 94.9% 
 
1514 91.4% 
     Yes 275 3.0% 
 
87 7.0% 
 
358 5.00% 
 
142 8.6% 
Hay fever 
           
     No 4791 79.7% 
 
703 82.9% 
 
4087 78.0% 
 
924 76.3% 
     Yes 1218 20.3% 
 
145 17.1% 
 
1151 22.0% 
 
287 23.7% 
HCV Serology 
           
    Negative 3688 96.8% 
 
491 95.0% 
 
2527 97.3% 
 
513 94.0% 
    Positive 120 3.2%   26 5.0%   70 2.7%   33 6.0% 
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Figure 1.  Prevalence of blood transfusion in the control group by region and study, adjusted for age at 
enrollment and sex 
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Figure 2.  Forest plot of the association of blood transfusion (ever, never) with risk of all NHL for non-Hispanic white men (A) and women (B) by 
geographic region 
(A) Men                                                 (B) Women 
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Figure 3.  Forest plot of the association of blood transfusion (ever, never) with risk of NHL 
subtypes for white men (A) and women (B) 
 
(A) Men 
(B) Women 
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SUPPLEMENTARY TABLE 1.  Characteristics of the pooled study participants by case-
control status 
 Cases (N=10,805)   Controls (N=14,026) 
  N %   N % 
Sex      
   Men 6108 56.5%  8119 57.9% 
   Women 4697 43.5%  5907 42.1% 
Age, Years      
   <20 13 0.1%  41 0.3% 
   20-29 307 2.8%  657 4.7% 
   30-39 787 7.3%  1416 10.1% 
   40-49 1558 14.4%  2054 14.6% 
   50-59 2643 24.5%  3121 22.3% 
   60-69 3200 29.6%  3791 27.0% 
   70-79 1990 18.4%  2524 18.0% 
   80+ 307 2.8%  422 3.0% 
Race/Ethnicity      
   Asian 307 2.8%  320 2.3% 
   Black 234 2.2%  342 2.4% 
   Hispanic 283 2.6%  318 2.3% 
   White 9707 89.8%  12772 91.0% 
   Other 274 2.5%  274 2.0% 
Education/Socioeconomic status      
   Low 4501 42.8%  5420 39.2% 
   Medium 3167 30.1%  4265 30.8% 
   High 2852 27.1%  4146 30.0% 
   Missing/Refuse 285   195  
NHL subtype*      
   Follicular 2537 23.5%    
   DLBCL 3262 30.2%    
   CLL/SLL 1442 13.3%    
   MCL 341 3.2%    
   MZL 723 6.7%    
      Nodal MZL 83     
      Splenic MZL 128     
      Extranodal MZL 398     
   LPL/WM 214 2.0%    
   BL/BL-like  189 1.7%    
   Other B-cell lymphoma 766 7.1%    
   T-cell lymphoma 598 5.5%    
      PTCL 320     
      MF/SS 202     
   Not otherwise specified 644 6.0%    
   Missing 89 0.8%       
*Abbreviations:  DLBCL, diffuse large B-cell lymphoma; CLL/SLL, chronic lymphocytic 
leukemia/small lymphocytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal 
zone lymphoma; LPL/WM, lymphoplasmatic lymphoma/Waldenstrom 
macroglobulinemia; BL, Burkitt lymphoma; PTCL, peripheral T-cell lymphoma; MF/SS, 
Mycosis Fungoides/Sezary Syndrome. 
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SUPPLEMENTARY TABLE 2.  Association of blood transfusion with risk of NHL by race/ethnicity 
  
Men 
 
Women 
Race/ 
Ethnicity  
Controls 
 
Cases 
    
Controls 
 
Cases 
   Transfusion exposure N %   N % OR 95% CI   N %   N % OR 95% CI 
Asian History of blood transfusion 
                 
 
   No 163 91.1% 
 
170 93.4% 1.00 reference 
 
116 88.5% 
 
97 83.6% 1.00 reference 
 
   Yes 16 8.9% 
 
12 6.6% 0.70 0.31 1.60 
 
15 11.5% 
 
19 16.4% 1.71 0.80 3.65 
 
Number of blood transfusions 
                 
 
   One 7 4.0% 
 
7 3.8% 0.83 0.27 2.54 
 
10 7.6% 
 
13 11.2% 1.67 0.68 4.10 
 
   Two or more 7 4.0% 
 
5 2.7% 0.80 0.24 2.72 
 
5 3.8% 
 
6 5.2% 1.76 0.50 6.23 
                   Black History of blood transfusion 
                 
 
   No 165 90.2% 
 
104 90.4% 1.00 reference 
 
122 79.2% 
 
87 75.0% 1.00 reference 
 
   Yes 18 9.8% 
 
11 9.6% 0.95 0.41 2.16 
 
32 20.8% 
 
29 25.0% 1.29 0.71 2.35 
 
Number of blood transfusions 
                 
 
   One 10 5.5% 
 
7 6.1% 1.08 0.38 3.05 
 
19 12.3% 
 
18 15.5% 1.29 0.63 2.67 
 
   Two or more 7 3.8% 
 
4 3.5% 1.03 0.28 3.73 
 
13 8.4% 
 
11 9.5% 1.30 0.54 3.13 
                   Hispanic History of blood transfusion 
                 
 
   No 154 92.2% 
 
120 90.9% 1.00 reference 
 
121 82.3% 
 
117 79.6% 1.00 reference 
 
   Yes 13 7.8% 
 
12 9.1% 1.14 0.48 2.71 
 
26 17.7% 
 
30 20.4% 1.08 0.58 2.02 
 
Number of blood transfusions 
                 
 
   One 10 6.0% 
 
10 7.7% 1.13 0.43 2.97 
 
17 11.6% 
 
18 12.3% 1.07 0.51 2.28 
 
   Two or more 2 1.2% 
 
0 0.0% 0.40 0.01 16.80 
 
9 6.1% 
 
11 7.5% 0.95 0.37 2.49 
                   White History of blood transfusion 
                 
 
   No 5473 86.9% 
 
4111 89.4% 1.00 reference 
 
4205 81.4% 
 
3307 81.4% 1.00 reference 
 
   Yes 824 13.1% 
 
488 10.6% 0.74 0.65 0.83 
 
997 18.6% 
 
754 18.6% 0.92 0.83 1.03 
 
Number of blood transfusions 
                 
 
   One 540 8.6% 
 
303 6.6% 0.70 0.60 0.81 
 
675 13.0% 
 
544 13.4% 1.00 0.89 1.14 
 
   Two or more 241 3.9% 
 
157 3.4% 0.85 0.65 1.00 
 
301 5.8% 
 
196 4.8% 0.76 0.63 0.92 
                   Other History of blood transfusion 
                 
 
   No 134 89.3% 
 
104 88.1% 1.00 reference 
 
94 79.7% 
 
99 81.1% 1.00 reference 
 
   Yes 16 10.7% 
 
14 11.9% 1.28 0.55 3.01 
 
24 20.3% 
 
23 18.9% 0.73 0.37 1.46 
 
Number of blood transfusions 
                 
 
   One 10 6.8% 
 
8 6.8% 1.24 0.41 3.73 
 
15 12.8% 
 
15 12.4% 0.86 0.38 1.94 
     Two or more 3 2.0%   6 5.1% 2.59 0.60 11.29   8 6.8%   7 5.8% 0.53 0.17 1.69 
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SUPPLEMENTARY FIGURE 1.  Prevalence of blood transfusion in the control group by age at 
enrollment and sex 
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SUPPLEMENTARY FIGURE 2.Prevalence (%) of ever having had a blood transfusion in controls by study 
design, adjusted for age and sex 
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SUPPLEMENTARY FIGURE 3.  Prevalence (%) and 95% confidence interval of blood transfusion in the 
control group by race/ethnicity and sex 
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SUPPLEMENTARY FIGURE 4.  Forest plot of association of blood transfusion (ever, never) race/ethnicity 
for men (A) and women (B) 
 
(A)  Men 
 
 
 
 
 
 
 
(B)  Women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
